Hudson Bay Capital Management’s Pacira BioSciences PCRX Stock Holding History

Hudson Bay Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$761K	–	485
2019 Q3	$761K	Buy	+20,000	New	+$798K	0.02%	329
2018 Q2	–	Sell	-61,000	Closed	-$1.9M	–	938
2018 Q1	$1.9M	Buy	+61,000	New	+$2.17M	0.04%	464

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Hudson Bay Capital Management's PCRX Position: Q4 2019 in Review

Hudson Bay Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 20,000 shares — an estimated $761K sold.

Hudson Bay Capital Management first reported a position in PCRX in Q1 2018 and held it in 2 quarters. The position peaked at $1.9M in Q1 2018. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

Hudson Bay Capital Management reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
Hudson Bay Capital Management sold 20,000 Pacira BioSciences shares in Q4 2019, an estimated $761K.
Hudson Bay Capital Management first reported a position in Pacira BioSciences in Q1 2018 and held it in 2 quarters.
Hudson Bay Capital Management's Pacira BioSciences position peaked at $1.9M in Q1 2018.
231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Hudson Bay Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.